LEADER 01968oam  2200433 a 450 
001 9910698695203321
005 20100106121949.0
035   $a(CKB)4950000000076398
035   $a(OCoLC)272396761
035   $a(EXLCZ)994950000000076398
100   $a20081117d2008      ua             0
101 0 $aeng
135   $aurbn|||||||||
181   $ctxt$2rdacontent
182   $cc$2rdamedia
183   $acr$2rdacarrier
200 10$aFollow-on biologics$b[electronic resource] $ehearing of the Committee on Health, Education, Labor, and Pensions, United States Senate, One Hundred Tenth Congress, first session, on examining Food and Drug Administration follow-on biologics, generally referred to as a biotechnology-derived protein drug (or biologic) that is comparable to a novel, previously approved biologic and that is approved with less supporting data than the innovator biologic, March 8, 2007
210  1$aWashington :$cU.S. G.P.O.,$d2008.
215   $a1 electronic text (iv, 78 pages) $cHTML, digital, PDF file
225 1 $aS. hrg. ;$v110-375
300   $aTitle from title screen (viewed on Nov. 17, 2008).
300   $aPaper version available for sale by the Supt. of Docs., U.S. G.P.O.
320   $aIncludes bibliographical references.
517   $aFollow-on biologics 
606   $aPharmaceutical biotechnology$xGovernment policy$zUnited States
606   $aPharmaceutical biotechnology$zUnited States$vPatents
606   $aPharmaceutical technology$xGovernment policy$zUnited States
606   $aDrug development$xGovernment policy$zUnited States
615  0$aPharmaceutical biotechnology$xGovernment policy
615  0$aPharmaceutical biotechnology
615  0$aPharmaceutical technology$xGovernment policy
615  0$aDrug development$xGovernment policy
801  0$bGPO
801  1$bGPO
801  2$bGPO
906   $aBOOK
912   $a9910698695203321
996   $aFollow-on biologics$93545334
997   $aUNINA